Titan Medical Expands Senior Leadership Team
April 22 2021 - 7:30AM
Business Wire
Kristen Galfetti Appointed as Vice President,
Investor Relations & Corporate Communications and Chien Huang
as Vice President, Finance
Titan Medical Inc. (“Titan” or the “Company”)
(TSX: TMD) (Nasdaq: TMDI), a medical
device company focused on the design and development of surgical
technologies for robotic single access surgery, today announced the
appointment of Kristen Galfetti, MBA, as its Vice President,
Investor Relations & Corporate Communications and Chien Huang
as Vice President Finance. Ms. Galfetti will be located in Boston
and Mr. Huang will be located in Toronto.
"It is a pleasure to welcome both Kristen and Chien to Titan
Medical. As the Titan team continues to grow and advance our Enos™
robotic single access surgery system toward human clinical studies,
we look forward to these two accomplished leaders significantly
contributing to our success," said David McNally, President and
Chief Executive Officer of Titan. "Kristen and Chien have each
demonstrated a record of success in their respective fields, and we
are proud that they have joined our leadership team."
Ms. Galfetti has over 20 years of experience leading investor
relations and corporate communications programs. Most recently, Ms.
Galfetti provided consulting services to small and medium companies
in the life science industries. Her corporate experience includes
serving as Vice President, Investor Relations & Corporate
Communications at Cynapsus Therapeutics. Prior to Cynapsus, she was
Senior Director, Investor Relations at Sanofi, responsible for
integrating the Genzyme Corporation investor relations program
post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director,
Corporate Communications and Investor Relations at AMAG
Pharmaceuticals. Prior to AMAG, Ms. Galfetti held Investor
Relations roles of increasing responsibility at Genzyme
Corporation. Ms. Galfetti holds a Bachelor of Arts in Political
Science from the University of Vermont and a Master of Business
Administration (with distinction) from Bentley University.
Mr. Huang is a financial executive with over 20 years of
experience developing and implementing financial models and
systems, and accounting practices to support the achievement of
strategic corporate objectives. Mr. Huang has strong expertise in
evaluating investment opportunities and long-term value creation as
well as extensive knowledge of IFRS and U.S. GAAP reporting
requirements. Most recently, he served as Senior Vice President,
Corporate Finance at Quarterhill Inc., where he led the finance
systems migration and reorganized key business processes,
streamlining external reporting processes. Prior to Quarterhill,
Mr. Huang served as Vice President, Finance at Aralez
Pharmaceuticals, responsible for implementing systems upgrades,
negotiating potential divestitures and advising on private equity
financing. Prior to this, Mr. Huang was Senior Director, Finance at
Astellas Pharma. Mr. Huang holds a Bachelor of Science in
Physiology from the University of Toronto, a Graduate Diploma in
Public Accountancy from McGill University, and has Chartered
Accountant Designation.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in
Toronto, is focused on developing robotic assisted technologies for
application in single access surgery. The Enos system, by Titan
Medical, is being developed with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, please visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
Company’s focus on the design and development of surgical
technologies for robotic single access surgery, the Enos system is
being developed with dual 3D and 2D high-definition vision systems,
multi-articulating instruments and an ergonomic surgeon
workstation, and that Titan intends to initially pursue gynecologic
surgical indications. These statements reflect management’s current
beliefs, and are based on information currently available to
management. Forward-looking statements involve significant risks,
uncertainties and assumptions. Many factors could cause the
Company’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including, without limitation, those
listed in the “Risk Factors” section of the Company’s Annual
Information Form and Form 40-F for the fiscal year ended December
31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210422005282/en/
Monique L. Delorme Chief Financial Officer (416) 548-7522
Kristen Galfetti Vice President, Investor Relations &
Corporate Communications (781) 869-2553
investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Sep 2023 to Sep 2024